Seattle-based biotech company HDT Bio closed a seed round totaling roughly $3 million to support work on its COVID-19 vaccine candidate HDT-301.
Researchers from HDT Bio and the University of Washington in July published a rapid-release paper in the
This website is built with Strikingly.
Create your FREE website today!
We just sent you an email. Please click the link in the email to confirm your subscription!
OKSubscriptions powered by Strikingly